Search

Author/Creator Leary, A

1. 972PBcl-2 proteins expression and response to navitoclax in platinum resistant/refractory recurrent ovarian cancer (PROC). (23rd October 2018)

Authors:
Brachet, P E; Joly Lobbedez, F; Fabbro, M; Leary, A; Medioni, J; Follana, P; Lesoin, A F; Frenel, J-S; Abadie Lacourtoisie, S; Floquet, A; Gladieff, L; You, B; Gavoille, C; Kalbacher, E; Briand, M; Just, P A; Blanc-Fournier, C; Giffard, F; Clarisse, B; Poulain, L
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 947PSubgroup analysis of rucaparib in platinum-sensitive recurrent ovarian carcinoma: Effect of prior chemotherapy regimens in ARIEL3. (23rd October 2018)

Authors:
Lorusso, D; Coleman, R L; Oza, A M; Aghajanian, C; Oaknin, A; Dean, A; Colombo, N; Weberpals, J I; Clamp, A R; Scambia, G; Leary, A; Holloway, R W; Amenedo Gancedo, M; Fong, P C; Goh, J C; O'Malley, D M; Banerjee, S; Goble, S; Cameron, T; Ledermann, J A
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. LBA3Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial. (25th November 2018)

Authors:
Friedlander, M; Moore, K; Colombo, N; Scambia, G; Kim, B-G; Oaknin, A; Lisyanskaya, A; Floquet, A; Leary, A; Sonke, G S; Gourley, C; Banerjee, S; Oza, A M; González-Martín, A; Aghajanian, C; Bradley, W; Lowe, E S; Bloomfield, R; Disilvestro, P
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. LBA10Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. (24th November 2019)

Authors:
Fujiwara, K; Harter, P; Leary, A; Perol, D; Pignata, S; González-Martín, A; Petru, E; van Nieuwenhuysen, E; Colombo, N; Mäenpää, J; Selle, F; de Gregorio, N; Lorusso, D; Guerra Alia, E M; Lefeuvre-Plesse, C; Buderath, P; Lortholary, A; Burges, A; Pujade-Lauraine, E; Ray-Coquard, I L
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. 224OPatient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). (24th November 2019)

Authors:
Friedlander, M L; Moore, K N; Colombo, N; Scambia, G; Kim, B-G; Oaknin, A; Lisyanskaya, A; Floquet, A; Leary, A; Sonke, G S; Gourley, C; Banerjee, S; Oza, A; González-Martín, A; Aghajanian, C; Bradley, W; Lowe, E; Hettle, R; Flood, E; Disilvestro, P
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. 2 Exploratory analysis of postprogression and patient-centered outcomes in ariel3: a phase 3, randomized, placebo-controlled study of rucaparib maintenance treatment in patients with recurrent ovarian carcinoma. (18th September 2019)

Authors:
Coleman, R; Oza, AM; Lorusso, D; Aghajanian, C; Oaknin, A; Dean, A; Colombo, N; Weberpals, JI; Clamp, AR; Scambia, G; Leary, A; Holloway, RW; Amenedo Gancedo, M; Fong, PC; Goh, JC; O'Malley, DM; Goble, S; Cameron, T; Bedel, J; Ledermann, JA
Journal:
International journal of gynecological cancer
Issue:
Volume 29(2019)Supplement 3
Page Start:
A1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Patient-centred outcomes in the phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: post hoc exploratory analyses by BRCA mutation status and patient age. (1st November 2019)

Authors:
Colombo, N; Oza, AM; Lorusso, D; Aghajanian, C; Oaknin, A; Dean, A; Weberpals, JI; Clamp, AR; Scambia, G; Leary, A; Holloway, RW; Amenedo Gancedo, M; Fong, PC; Goh, JC; O'Malley, DM; Armstrong, DK; Banerjee, S; García-Donas, J; Swisher, EM; Meunier, J
Journal:
International journal of gynecological cancer
Issue:
Volume 29(2019)Supplement 4
Page Start:
A28
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the Phase III SOLO1 trial. (1st November 2019)

Authors:
Moore, K; Colombo, N; Scambia, G; Kim, B-G; Oaknin, A; Friedlander, M; Lisyanskaya, A; Floquet, A; Leary, A; Sonke, GS; Gourley, C; Banerjee, S; Oza, A; González-Martín, A; Aghajanian, C; Bradley, W; Mathews, C; Liu, J; Lowe, ES; Bloomfield, R
Journal:
International journal of gynecological cancer
Issue:
Volume 29(2019)Supplement 4
Page Start:
A14
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗